[go: up one dir, main page]

MX2023010063A - Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. - Google Patents

Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.

Info

Publication number
MX2023010063A
MX2023010063A MX2023010063A MX2023010063A MX2023010063A MX 2023010063 A MX2023010063 A MX 2023010063A MX 2023010063 A MX2023010063 A MX 2023010063A MX 2023010063 A MX2023010063 A MX 2023010063A MX 2023010063 A MX2023010063 A MX 2023010063A
Authority
MX
Mexico
Prior art keywords
methods
disubstituted
pyrazolyl steroid
steroid
pyrazolyl
Prior art date
Application number
MX2023010063A
Other languages
English (en)
Inventor
Stephen Jay Kanes
James J Doherty
Jeffrey M Jonas
Inderjit Kaul
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2023010063A publication Critical patent/MX2023010063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proveen métodos para tratar un trastorno del sueño, por ej., insomnio, en un sujeto, que comprende administrar al sujeto una cantidad efectiva de un compuesto que tiene la fórmula: (ver Fórmula) Compuesto 1 o una sal farmacéuticamente aceptable del mismo.
MX2023010063A 2017-09-14 2020-03-13 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. MX2023010063A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762558703P 2017-09-14 2017-09-14
US201862624678P 2018-01-31 2018-01-31
US201862624680P 2018-01-31 2018-01-31
US201862653189P 2018-04-05 2018-04-05

Publications (1)

Publication Number Publication Date
MX2023010063A true MX2023010063A (es) 2023-09-06

Family

ID=65723895

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020002889A MX2020002889A (es) 2017-09-14 2018-09-14 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo.
MX2023010063A MX2023010063A (es) 2017-09-14 2020-03-13 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2023010064A MX2023010064A (es) 2017-09-14 2020-03-13 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002889A MX2020002889A (es) 2017-09-14 2018-09-14 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023010064A MX2023010064A (es) 2017-09-14 2020-03-13 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.

Country Status (9)

Country Link
US (2) US20220110949A1 (es)
EP (2) EP4218767A1 (es)
JP (3) JP2020534270A (es)
AU (2) AU2018334214A1 (es)
CA (1) CA3075872A1 (es)
IL (2) IL303083A (es)
MX (3) MX2020002889A (es)
TW (2) TW202339764A (es)
WO (1) WO2019055764A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59734B1 (sr) 2012-01-23 2020-02-28 Sage Therapeutics Inc Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
EP2887944B1 (en) 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
KR102614507B1 (ko) 2013-04-17 2023-12-19 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
KR20230079470A (ko) 2016-08-23 2023-06-07 세이지 테라퓨틱스, 인크. 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
KR20220112803A (ko) * 2019-12-05 2022-08-11 세이지 테라퓨틱스, 인크. 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102614507B1 (ko) * 2013-04-17 2023-12-19 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3206493B1 (en) * 2014-10-16 2020-05-06 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
KR20230079470A (ko) * 2016-08-23 2023-06-07 세이지 테라퓨틱스, 인크. 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드

Also Published As

Publication number Publication date
TW202339764A (zh) 2023-10-16
MX2023010064A (es) 2023-09-06
JP2023038310A (ja) 2023-03-16
AU2024205601A1 (en) 2024-08-29
AU2018334214A1 (en) 2020-03-26
JP2020534270A (ja) 2020-11-26
MX2020002889A (es) 2020-10-01
CA3075872A1 (en) 2019-03-21
EP4218767A1 (en) 2023-08-02
JP2024107137A (ja) 2024-08-08
TW201919642A (zh) 2019-06-01
US20230201224A1 (en) 2023-06-29
IL273126A (en) 2020-04-30
WO2019055764A1 (en) 2019-03-21
IL303083A (en) 2023-07-01
US20220110949A1 (en) 2022-04-14
EP3681510A1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
MX2023010064A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2021002321A (es) Nuevos metodos.
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
MY179696A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
EA033689B9 (ru) Ингибиторы g12c kras
PH12018501903B1 (en) Methods of treating depression using orexin-2 receptor antagonists
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
TW201613578A (en) Pharmaceutical combinations
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
MY203645A (en) Ret inhibitor for use in treating cancer having a ret alteration
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.